Magnesium Treating Subarachnoid Hemorrhage Vasospasm
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT04613960
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT04613960
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Unknown status
Technical summary
Registry record NCT04613960. Randomized; quadruple masking; primary purpose prevention. Start 2022-12 (anticipated); primary completion 2023-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Magnesium Treating Subarachnoid Hemorrhage Vasospasm
- Acronym
- MATSH-SHapE
- Condition
- Subarachnoid Hemorrhage, Aneurysmal
- Condition
- Cerebral Vasospasm
- Intervention (Drug)
- Magnesium sulfate
- Intervention (Drug)
- normal saline
- Lead sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
- Collaborator
- Ain Shams University
- Collaborator
- Health Insurance Organization, Egypt
Record details
- Record id
cardio:ct-nct04613960- Content hash
194358fd029dbf2edb37d53d15fc2340c293dd7cc4db3513ecc9af7abb37e8a6